10 March 2026 • 1 minute read
China’s life sciences boom: Navigating risk for growth
WebinarTuesday, March 10, 2026
China’s life sciences sector is experiencing rapid expansion, driven by innovation, regulatory reforms, and increasing global collaboration. For companies and investors, this growth could present significant opportunities – and complex challenges. Geopolitical shifts, evolving trade policies, and regulatory uncertainties could impact market entry and long-term strategy.
A panel of DLA Piper attorneys explored:
- Key drivers of growth in China’s life sciences industry
- Strategic considerations for mergers and acquisitions, partnerships, licensing, and investment
- Managing geopolitical and compliance risks in cross-border transactions
- Changes resulting from the BIOSECURE Act and the operational steps life sciences and investors can take now
This session provided practical insights for life sciences executives, investors, and legal teams seeking to engage with China’s dynamic market while mitigating risk.
For more information
Please contact Camille Tanksley.
Watch the video
Emilio Ragosa
Partner
Regional Office Head for Baltimore Corporate & Securities Group
Howard Schwartz
Partner
Regional Office Head for Baltimore Corporate & Securities Group
Regional Office Head for Baltimore Corporate & Securities Group
Josh Kaufman
Partner, Co-Chair, Capital Markets and Public Company
Advisory Practice US-LatAm Practice Group Regional Co-Leader, Capital Markets
Advisory Practice US-LatAm Practice Group Regional Co-Leader, Capital Markets
Jamie Gregorian
Of Counsel
